Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Continuous Glucose Monitoring
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
54%
Severe Hyperglycemia
50%
Hyperglycemia
36%
Point-of-care Glucose
23%
Glucose Level
22%
Diabetes Technology
16%
Relative Difference
16%
Error Grid Analysis
16%
Glucose Measurement
15%
History of Diabetes
15%
Chimeric Antigen Receptor T-cell Therapy
15%
Dysglycemia
14%
Point-of-care
14%
Insulin Dosing Error
8%
Hematological Treatment
8%
Adult Patients
8%
Measurement Method
8%
Under-report
8%
Hematological Malignancies
8%
Capillary Measurement
8%
Close Monitoring
8%
Treatment Outcome
8%
Glucose Values
8%
Clinical Accuracy
8%
Treatment Modalities
8%
Monitoring Measurement
8%
Metabolic
8%
Capillary
8%
Type 1 Diabetes Mellitus (T1DM)
8%
Early Detection
7%
Cell Treatment
7%
Glucose Monitoring
7%
Improved Outcomes
7%
Improved Detection
7%
High-dose Chemotherapy
7%
Prolonged Hospitalization
7%
Acceptable Zones
7%
Adverse Clinical Outcomes
7%
Physiological Stress
7%
Clarke Error Grid Analysis
7%
Corticosteroids
7%
Chimeric Antigen Receptor T Cells (CAR-T)
7%
Total Parenteral nutrition
7%
Diabetes
7%
Patient Demographics
7%
Mean Absolute Relative Difference
7%
Medicine and Dentistry
Prospective Study
100%
Hyperglycemia
75%
Autologous Stem Cell Transplantation
66%
Diabetes
66%
Allogeneic Stem Cell Transplantation
58%
Capillary
50%
Chimeric Antigen Receptor T-Cell Immunotherapy
33%
Hemostat
25%
Hematologic Malignancy
25%
Diabetes Mellitus
25%
Dysglycemia
16%
Patient Population
8%
Patient Care
8%
Total Parenteral Nutrition
8%
Cytokine
8%
Chimeric Antigen Receptor T-Cell
8%
High Dose Chemotherapy
8%
Immunosuppressant
8%
Physiological Stress
8%
Nursing and Health Professions
Continuous Glucose Monitoring
100%
Hyperglycemia
58%
Autologous Stem Cell Transplantation
30%
Allogeneic Stem Cell Transplantation
23%
Glucose Level
22%
Capillary
16%
Chimeric Antigen Receptor T-Cell Immunotherapy
15%
Dysglycemia
14%
Treatment Outcome
8%
Diabetes Mellitus
8%
Hematologic Malignancy
8%
Hemostatic Agent
8%
Chimeric Antigen Receptor T-Cell
7%
Total Parenteral Nutrition
7%
Patient Care
7%
Drug Megadose
7%
Clinical Outcome
7%
Patient Population
7%
Immunosuppressive Agent
7%